Featured post

#Analysis of recent #scientific #information on #avian #influenza A(#H7N9) virus - 10 February 2017 (@WHO, edited)

  Title : #Analysis of recent #scientific #information on #avian #influenza A(#H7N9) virus - 10 February 2017. Subject : Avian Influenza, ...

5 Jun 2013

Transmission of multidrug-resistant tuberculosis in the USA: a cross-sectional study (The Lancet Infect Dis., abstract, edited)

[Source: The Lancet Infectious Diseases, full text: (LINK). Abstract, edited.]

The Lancet Infectious Diseases, Early Online Publication, 5 June 2013


Transmission of multidrug-resistant tuberculosis in the USA: a cross-sectional study

Original Text

Dr Patrick K Moonan DrPH a, Larry D Teeter PhD b, Katya Salcedo MPH c, Smita Ghosh MS a, Shama D Ahuja PhD d, Jennifer Flood MD c, Edward A Graviss PhD b




Multidrug-resistant (MDR) tuberculosis is a potential threat to tuberculosis elimination, but the extent of MDR tuberculosis disease in the USA that is attributable to transmission within the country is unknown. We assessed transmission of MDR tuberculosis and potential contributing factors in the USA.


In a cross-sectional study, clinical, demographic, epidemiological, and Mycobacterium tuberculosis genotype data were obtained during routine surveillance of all verified cases of MDR tuberculosis reported from eight states in the USA (California from Jan 1, 2007, to Dec 31, 2009; Texas from Jan 1, 2007, to March 31, 2009; and the states of Colorado, Maryland, Massachusetts, New York, Tennessee, and Washington from Jan 1, 2007 to Dec 31, 2008). In-depth interviews and health-record abstraction were done for all who consented to ascertain potential interpersonal connections.


168 cases of MDR tuberculosis were reported in the eight states during our study period. 92 individuals (55%) consented to in-depth interview. 20 (22%) of these individuals developed MDR tuberculosis as a result of transmission in the USA; a source case was identified for eight of them (9%). 20 individuals (22%) had imported active tuberculosis (ie, culture-confirmed disease within 3 months of entry into the USA). 38 (41%) were deemed to have reactivation of disease, of whom 14 (15%) had a known previous episode of tuberculosis outside the USA. Five individuals (5%) had documented treatment of a previous episode in the USA, and so were deemed to have relapsed. For nine cases (10%), insufficient evidence was available to definitively classify reason for presentation.


About a fifth of cases of MDR tuberculosis in the USA can be linked to transmission within the country. Many individuals acquire MDR tuberculosis before entry into the USA. MDR tuberculosis needs to be diagnosed rapidly to reduce potential infectious periods, and clinicians should consider latent tuberculosis infection treatment—tailored to the results of drug susceptibility testing of the putative source case—for exposed individuals.


Centers for Disease Control and Prevention.


a Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA, USA; b Department of Pathology and Genomic Medicine, The Methodist Hospital Research Institute, Houston, TX, USA; c Division of Communicable Disease Control, Center for Infectious Diseases, California Department of Public Health, Richmond, CA, USA; d Bureau of Tuberculosis Control, New York City Department of Health and Mental Hygiene, New York, NY, USA

Correspondence to: Dr Patrick K Moonan, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop E-10, Atlanta, GA 30333, USA